{"id":31148,"date":"2020-08-18T16:00:00","date_gmt":"2020-08-18T14:00:00","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=31148"},"modified":"2024-03-22T11:01:14","modified_gmt":"2024-03-22T10:01:14","slug":"flexible-corona","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science\/flexible-corona\/","title":{"rendered":"Flexible and protected \u2013 new findings on SARS-CoV-2 protein shed light on virus\u2019s ability to infect cells"},"content":{"rendered":"\n

At the start of a COVID-19 infection, the coronavirus SARS-CoV-2 docks onto human cells using the spike-like proteins on its surface. The spike protein is at the centre of vaccine development because it triggers an immune response in humans. A group of German scientists, including members of EMBL in Heidelberg, the Max Planck Institute of Biophysics<\/a>, the Paul-Ehrlich-Institut<\/a>, and Goethe University Frankfurt<\/a> have focused on the surface structure of the virus to gain insights they can use for the development of vaccines and of effective therapeutics to treat infected patients.<\/p>\n\n\n\n

The team combined cryo-electron tomography, subtomogram averaging, and molecular dynamics simulations to analyse the molecular structure of the spike protein in its natural environment, on intact virions, and with near-atomic resolution. Using EMBL\u2019s state-of-the-art cryo-electron microscopy imaging facility<\/a>, 266 cryotomograms of about 1000 different viruses were generated, each carrying an average of 40 spikes on its surface. Subtomogram averaging and image processing, combined with molecular dynamics simulations, finally provided the important and novel structural information on these spikes.<\/p>\n\n\n\n

The results were surprising: the data showed that the globular portion of the spike protein, which contains the receptor-binding region and the machinery required for fusion with the target cell, is connected to a flexible stalk. \u201cThe upper spherical part of the spike has a structure that is well reproduced by recombinant proteins used for vaccine development,\u201d explains Martin Beck, EMBL group leader and a director of the Max Planck Institute (MPI) of Biophysics. \u201cHowever, our findings about the stalk, which fixes the globular part of the spike protein to the virus surface, were new.\u201d<\/p>\n\n\n\n

\n